During our research, we identified 96 cancer biomarkers testing solutions. It is interesting to highlight that 50 companies are engaged in providing such testing solutions. In order to meet the increasing demand for biomarker-based testing solutions, these companies have undertaken several initiatives, such as conducting clinical trials, publishing research articles and expanding their existing capabilities / product portfolios.

The cancer biomarker market size is projected to grow from $ 28.6 billion in 2024 to $ 46.7 billion by 2035, representing a CAGR of 5% during the forecast period from 2024 to 2035.

Majority (66%) of the testing solutions use genomics technology for profiling cancer biomarkers. This can be attributed to the fact that genomics technology has the capability to provide extensive genetic information that can be utilized for early detection, prognosis, guiding treatment and developing targeted therapies.  Further, it is important to highlight that around 25% of the testing solutions use immunoassay for profiling cancer biomarkers. Examples of solutions that use genomics technology include (in alphabetical order) Cancer All-In-One Solid Tumor Assay (Agilent), CleanPlex TMB Panel (Paragon Genomics), GuardantOMNI (Guardant Health), MI Tumor Seek (Caris Life Sciences) and OmniSeq INSIGHT (Labcorp).

Turnaround time is defined as the total time between receiving a specimen at the laboratory and the final dispatch of the results to the customer. It is one of the most important parameters and is often used as a key performance indicator for evaluating the performance of a laboratory. We came across 21 testing solutions that have an average turnaround time of 10-15 days. Only a few testing solutions (10) have a turnaround time of less than 5 days; examples include (in alphabetical order) CleanPlex TMB Panel (Paragon Genomics), ddPCR Microsatellite Instability (MSI) Kit (Bio-Rad), FOXP3 Assay (PhenoPath) and IdyllaTM MSI Test (Biocartis).

Further, majority (73%) of the cancer biomarker testing solutions assists in the evaluation of MSI / MMR, followed by 47% testing solutions evaluating TMB. It is worth highlighting that over 35% of the testing solutions offer assessments for both MSI/MMR and TMB. Notable examples of testing solutions focused on the evaluation of both MSI / MMR and TMB include (in alphabetical order) Altera Comprehensive Genomic Profiling (Natera), CancerPrecision (CeGaT), FoundationOne CDx (Foundation Medicine), PGDx elio plasma complete (Personal Genome Diagnostics) and Tempus xT Solid Tumor (Tempus).

The field of cancer biomarkers has seen a significant rise in research, with over 470 articles published by various researchers, underscoring the growing focus of several industry players and academic players in this domain. During our research, we came across 476 articles focused on cancer biomarkers that have been published in this domain.

It is worth mentioning that the maximum number of articles were published in 2022, followed by articles published in the year 2023 (143). Notably, majority of the publications are focused on the diagnosis of lung cancer using cancer biomarkers. This is followed by articles published for breast cancer (15%), gastrointestinal cancer and kidney cancer (14% each).

In addition, the journal Nature Medicine emerged as the most popular journal with the highest impact factor of 87.241. This is followed by Journal of Clinical Oncology, with an impact factor of 50.717.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/cancer-biomarkers-market/253.html

Browse More Related Reports

https://www.olvera-street.com/post/olvera-street-com-will-be-returning-to-the-venice-biennale-arte-2022?commentId=a4e8340f-9951-4b13-8942-e8b18b95af55

https://www.basqueculinaryworldprize.com/winner-2019/myint-en-bcc-3-2/#comment-622365

https://www.smitefire.com/profile/chris5911-182142?profilepage

https://www.openrec.tv/user/but0es2mo81qg4dovhuf/about

https://vieclamdn.net/members/chrisgayle00.7584/#about

https://www.chichi-pui.com/users/chris009/

https://www.asklent.com/user/Gayle6660#gsc.tab=0

https://maxforlive.com/profile/user/gayle77?tab=devices

https://www.dcfever.com/users/profile.php?id=1215558

https://tawk.to/54ca3ef2bca7c63e990ceb1a72b0f6e084bf9350?_gl=1*48do5b*_ga*MTI2NDU4MTkxNy4xNzMxOTEyNTI0*_ga_ZJL9LF36Z8*MTczMTkxMjUyNC4xLjEuMTczMTkxMjk5MC4wLjAuMA

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.                   

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:

Roots Analysis

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]

Website: https://www.rootsanalysis.com/